SEC Info - Outlook Therapeutics, Inc.

SEC Info℠

Home

My Interests

Help

Please Sign In

Outlook Therapeutics, Inc.
NJ
SEC # 1649989

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

2/8/24	DEF 14A	1	A-1	2
5/6/24	424B3	1	About This Prospectus	9
4/12/24	424B5	1	About This Prospectus Supplement	2
2/8/24	DEF 14A	1	Analysis of the Information Presented in the Pay versus Performance Table	2
		1	Appendix A	2
		1	Appendix B	2
		1	Appendix C	2
		1	B-1	2
		1	Board Diversity	2
		1	Board Leadership Structure	2
12/22/23	10-K	1	Business	1
2/8/24	DEF 14A	1	C-1	2
12/22/23	10-K	1	Cautionary Note Regarding Forward-Looking Statements and Industry Data	1
2/8/24	DEF 14A	1	Certain Material U.S. Federal Income Tax Consequences of the Reverse Stock Split	2
1/24/24	10-K/A	1	Certain Relationships and Related Transactions, and Director Independence	2
2/8/24	DEF 14A	1	Certain Risks Associated with the Reverse Stock Split	2
12/22/23	10-K	1	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	1
2/8/24	DEF 14A	1	Clawback Policy	2
		1	Code of Ethics	2
12/22/23	10-K	1	Consolidated Balance Sheets	1
2/14/24	10-Q	1	Consolidated Balance Sheets as of December 31, 2023 and September 30, 2023	1
8/14/23	10-Q	1	Consolidated Balance Sheets as of June 30, 2023 and September 30, 2022	1
5/15/23	10-Q	1	Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022	1
12/22/23	10-K	1	Consolidated Financial Statements and Supplementary Data	1
		1	Consolidated Statements of Cash Flows	1
8/14/23	10-Q	1	Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2023 and 2022	1
5/15/23	10-Q	1	Consolidated Statements of Cash Flows for the Six Months Ended March 31, 2023 and 2022	1
2/14/24	10-Q	1	Consolidated Statements of Cash Flows for the Three Months Ended December 31, 2023 and 2022	1
12/22/23	10-K	1	Consolidated Statements of Operations	1
8/14/23	10-Q	1	Consolidated Statements of Operations for the Three and Nine Months Ended June 30, 2023 and 2022	1
5/15/23	10-Q	1	Consolidated Statements of Operations for the Three and Six Months Ended March 31, 2023 and 2022	1
2/14/24	10-Q	1	Consolidated Statements of Operations for the Three Months Ended December 31, 2023 and 2022	1
8/14/23	10-Q	1	Consolidated Statements of Stockholders' (Deficit) Equity for the Three and Nine Months Ended June 30, 2023 and 2022	1
2/14/24	10-Q	1	Consolidated Statements of Stockholders' (Deficit) Equity for the Three Months Ended December 31, 2023 and 2022	1
12/22/23	10-K	1	Consolidated Statements of Stockholders' Equity	1
5/15/23	10-Q	1	Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended March 31, 2023 and 2022	1
2/14/24	10-Q	1	Controls and Procedures	4
2/8/24	DEF 14A	1	Convertible Promissory Note, The	2
		1	Corporate Governance Guidelines	2
2/14/24	10-Q	1	Defaults Upon Senior Securities	3
4/12/24	424B5	1	Description of Capital Stock	3
		1	Description of Debt Securities	3
		1	Description of Warrants	3
		1	Dilution	2
2/8/24	DEF 14A	1	Director Compensation	2
1/24/24	10-K/A	1	Directors, Executive Officers and Corporate Governance	2
2/8/24	DEF 14A	1	Effect of the Private Placement Share Issuance Proposal on Current Stockholders	2
		1	Effective Date	2
		1	Effects of the Increase in Authorized Shares	2
		1	Effects of the Reverse Stock Split	2
		1	Employment and Other Compensation Arrangements, Equity Plan Awards	2
		1	Equity Compensation Plan Information	2
		1	Executive Compensation	4
		1	Executive Officers of the Company	2
2/14/24	10-Q	1	Exhibits	3
1/24/24	10-K/A	1	Exhibits and Financial Statement Schedules	2
5/6/24	424B3	1	Experts	9
2/8/24	DEF 14A	1	Family Relationships	2
2/14/24	10-Q	1	Financial Statements (Unaudited)	3
1/24/24	10-K/A	1	Form 10-K Summary	2
2/8/24	DEF 14A	1	GMS Ventures & Investments	2
		1	Hedging Transactions	2
		1	Householding of Proxy Materials	2
8/14/23	S-3	1	Ii-1	1
5/6/24	424B3	1	Incorporation of Certain Information by Reference	9
2/8/24	DEF 14A	1	Indemnification Agreements	2
		1	Independence of the Board of Directors	2
		1	Information Regarding Committees of the Board of Directors	2
		1	Information Regarding the Board of Directors and Corporate Governance	2
		1	Interests of Certain Parties	2
12/22/23	10-K	1	Item 1	1
1/24/24	10-K/A	1	Item 10	2
		1	Item 11	2
		1	Item 12	2
		1	Item 13	2
		1	Item 14	2
		1	Item 15	2
		1	Item 16	2
12/22/23	10-K	1	Item 1A	1
		1	Item 1B	1
		1	Item 2	1
		1	Item 3	1
		1	Item 4	1
		1	Item 5	1
		1	Item 7	1
		1	Item 7A	1
		1	Item 8	1
		1	Item 9	1
		1	Item 9A	1
		1	Item 9B	1
5/6/24	424B3	1	Legal Matters	9
4/12/24	424B5	1	Legal Ownership of Securities	3
2/14/24	10-Q	1	Legal Proceedings	4
		1	Management's Discussion and Analysis of Financial Condition and Results of Operations	4
12/22/23	10-K	1	Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	1
2/8/24	DEF 14A	1	Meetings of the Board of Directors	2
2/14/24	10-Q	1	Mine Safety Disclosures	4
2/8/24	DEF 14A	1	Narrative to Summary Compensation Table	2
		1	Nasdaq Listing Compliance	2
		1	No Dissenters' Rights	2
		1	No Fractional Shares	2
		1	Nominees for Election	2
		1	Non-Employee Director Compensation Policy	2
12/22/23	10-K	1	Notes to Consolidated Financial Statements	1
2/14/24	10-Q	1	Notes to Unaudited Interim Consolidated Financial Statements	3
4/12/24	424B5	1	Offering, The	4
2/14/24	10-Q	1	Other Information	4
2/8/24	DEF 14A	1	Other Matters	2
		1	Outstanding Equity Awards at Fiscal Year End	2
		1	Overview	2
12/22/23	10-K	1	Part I	1
2/14/24	10-Q	1	Part I. Financial Information	3
12/22/23	10-K	1	Part Ii	1
8/14/23	S-3	1	Part Ii Information Not Required in Prospectus	1
2/14/24	10-Q	1	Part Ii. Other Information	3
1/24/24	10-K/A	1	Part Iii	2
		1	Part Iv	2
2/8/24	DEF 14A	1	Pay Versus Performance	2
5/6/24	424B3	1	Plan of Distribution	9
2/8/24	DEF 14A	1	Potential Effects of Non-Approval of this Proposal	2
		1	Potential Effects of this Proposal	2
4/26/24	S-3	1	Power of Attorney (included on signature page)	2
3/28/24	S-3	1	Power of Attorney (included on the signature page to this registration statement)	1
3/28/24	S-8	1	Power of Attorney (see signature page hereto)	1
8/14/23	S-3	1	Power of Attorney (see signature page to this registration statement)	1
2/8/24	DEF 14A	1	Pre-Approval Policies and Procedures	2
		1	Principal Accountant Fees and Services	3
12/22/23	10-K	1	Principal Accounting Fees and Services	1
2/8/24	DEF 14A	1	Private Placements, The	2
12/22/23	10-K	1	Properties	1
2/8/24	DEF 14A	1	Proposal 1 Election of Directors	2
		1	Proposal 2 Approval of Private Placement Share Issuance Proposal	2
		1	Proposal 3 Approval of Convertible Note Share Issuance Proposal	2
		1	Proposal 4 Approval of Authorized Share Increase Proposal	2
		1	Proposal 5 Approval of the Officer Exculpation Proposal	2
		1	Proposal 6 Approval of the Reverse Stock Split Proposal	2
		1	Proposal 7 Ratification of Selection of Independent Registered Public Accounting Firm	2
		1	Proposal 8 Advisory Vote on Executive Compensation	2
5/6/24	424B3	1	Prospectus Summary	9
4/12/24	424B5	1	Prospectus Supplement Summary	2
2/14/24	10-Q	1	Quantitative and Qualitative Disclosures About Market Risk	4
2/8/24	DEF 14A	1	Questions and Answers About the Annual Meeting	2
		1	Reasons for and Effects of the Officer Exculpation Proposal	2
		1	Reasons for the Increase in Authorized Shares	2
		1	Reasons for the Reverse Stock Split	2
		1	Related-Party Transaction Policy	2
12/22/23	10-K	1	Report of Independent Registered Public Accounting Firm	1
2/8/24	DEF 14A	1	Report of the Audit Committee of the Board of Directors	2
5/6/24	424B3	1	Risk Factors	13
2/8/24	DEF 14A	1	Role of the Board in Risk Oversight	2
4/12/24	424B5	1	S-1	2
5/16/23	424B5	1	S-10	1
4/12/24	424B5	1	S-11	2
		1	S-12	1
5/16/23	424B5	1	S-13	1
4/12/24	424B5	1	S-14	1
5/16/23	424B5	1	S-15	1
4/12/24	424B5	1	S-16	1
		1	S-17	1
		1	S-18	1
		1	S-19	1
		1	S-2	2
		1	S-5	2
5/16/23	424B5	1	S-6	1
4/12/24	424B5	1	S-7	1
5/16/23	424B5	1	S-8	1
4/12/24	424B5	1	S-9	1
		1	Securities We May Offer, The	3
2/8/24	DEF 14A	1	Security Ownership of Certain Beneficial Owners and Management	2
1/24/24	10-K/A	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	2
12/22/23	10-K	1	Selected Risks Affecting Our Business	1
5/6/24	424B3	1	Selling Stockholder	4
4/1/24	424B3	1	Selling Stockholders	2
2/14/24	10-Q	1	Signatures	4
5/6/24	424B3	1	Special Note Regarding Forward-Looking Statements	9
2/8/24	DEF 14A	1	Stockholder Communications with the Board of Directors	2
		1	Summary Compensation Table	2
		1	Syntone Ventures LLC	2
2/14/24	10-Q	1	Table of Contents	10
2/8/24	DEF 14A	1	The Convertible Promissory Note	2
4/12/24	424B5	1	The Offering	4
2/8/24	DEF 14A	1	The Private Placements	2
4/12/24	424B5	1	The Securities We May Offer	3
2/8/24	DEF 14A	1	Transactions With Related Persons	2
2/14/24	10-Q	1	Unregistered Sales of Equity Securities and Use of Proceeds	3
12/22/23	10-K	1	Unresolved Staff Comments	1
5/6/24	424B3	1	Use of Proceeds	9
2/8/24	DEF 14A	1	Vote Required	2
5/6/24	424B3	1	Where You Can Find Additional Information	6
4/12/24	424B5	1	Where You Can Find More Information	3
2/8/24	DEF 14A	1	Why We Need Stockholder Approval	2
3/28/24	S-8	1	24.1	2

↑Top

Outlook Therapeutics, Inc. NJ SEC # 1649989

440 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

Outlook Therapeutics, Inc.
NJ
SEC # 1649989

440 Topics
within the